Albert David ₹5 Dividend FY26 | Record Date, Yield, Sustainability

At its board meeting on 12 May 2026, the Board of Albert David Limited recommended a final dividend of ₹5.00 per equity share (50% of the ₹10 face value) for the financial year ended 31 March 2026. The recommendation is subject to shareholder approval at the company's 87th Annual General Meeting, scheduled for 6 August 2026 via video conferencing.

The same board meeting also saw the appointment of Mr. Amit Mahla as Chief Executive Officer with effect from 12 May 2026, following the earlier resignation of Mr. Umesh Manohar Kunte as MD & CEO in December 2025. A leadership transition alongside a loss-making year is worth flagging for readers assessing near-term direction, even though it does not directly change the dividend mechanics.

The register of members and share transfer books will remain closed from 31 July 2026 to 6 August 2026 (both days inclusive). The statutory auditors, L. B. Jha & Co. LLP, issued an unmodified (clean) audit opinion on the FY26 results — there are no audit qualifications on the numbers discussed below.

Yield reality check

A ~0.70% yield is low — well below the healthcare sector average dividend yield of roughly 1.66% (source: TipRanks sector data). Importantly, this is not a case of yield being flattered by a falling price. Although the stock is down around 12% over the past year, the yield stays modest because the absolute dividend was cut from ₹11.50 (FY24) to ₹5.00 (FY25) and held there. So the low yield reflects a genuinely smaller payout, not a distressed-price signal. Investors buying purely for income should note the yield is thin relative to a bank fixed deposit.

Why did profit collapse when revenue only fell 3.5%? — the non-obvious answer

Most wire reports will simply say "Albert David swung to a loss." The real driver is not the core pharma business — it is the investment book. Albert David holds about ₹276 crore in cash and market investments, and the mark-to-market movement on that portfolio flows straight through the profit-and-loss account. In FY25 those investments delivered a fair-value gain of roughly ₹19.8 crore; in FY26 they swung to a fair-value loss of about ₹3.9 crore. That single reversal — visible in the collapse of "other income" from ₹29.58 crore to ₹7.45 crore — explains the bulk of the profit swing. The March-2026 quarter alone carried a negative other-income line of ₹24.84 crore, which is what pushed Q4 to a ₹21.4 crore loss.

The flip side: the core business actually stabilised late in the year

In the fourth quarter, revenue from operations rose to ₹85.86 crore, a +14.65% year-on-year increase. So while the full-year headline is a loss, the underlying pharmaceutical sales showed signs of recovery in the final quarter even as the accounting result was dragged down by investment mark-downs and higher finance and depreciation charges. Both facts are true and readers deserve both.

Reported profit is an opinion; cash is a fact — and the cash is negative

Even setting aside the loss, the company generated negative ₹7.66 crore of operating cash in FY26. A big reason is working capital: trade receivables rose about 24% to ₹33.92 crore even as revenue fell 3.5% — meaning the company is collecting from customers more slowly than it is selling. After ₹29.1 crore of capital expenditure (largely capital work-in-progress, which more than doubled to ₹20.77 crore), free cash flow was deeply negative at about −₹36.8 crore.

So how is the dividend being paid?

Not from current earnings and not from free cash flow. During FY26 the company actually raised ₹18.43 crore of fresh short-term borrowings (net) and its total current borrowings rose to ₹28.48 crore. The ₹2.86 crore dividend paid during the year (the FY25 dividend) and the upcoming ₹2.85 crore FY26 payout are ultimately being met from the company's large accumulated cash-and-investment reserves. This is affordable — but it is a return of capital from the balance sheet in a weak year, not a distribution of freshly generated profit.

This is the crux of the whole story: Albert David is a fortress balance sheet attached to a currently sub-scale operating business. The ₹276 crore investment-and-cash pile is more than two-thirds of the entire market capitalisation of roughly ₹405 crore. That cash makes the small ₹2.85 crore dividend trivially affordable — cash covers it about 97 times over — but it also means the operating business is being valued very modestly by the market once you strip the cash out. Debt is minimal, so there is no solvency concern.

The honest read: this dividend is safe in the sense that the company can easily afford it, but it is not "high quality" in the sense that it is not being earned by the operating business right now. The board already demonstrated it will cut when needed (FY24 ₹11.50 → FY25 ₹5.00). If operating performance keeps deteriorating, a further reset to the dividend cannot be ruled out — the balance sheet gives flexibility, not a guarantee.

Against peers, Albert David is a below-average yielder in a sector that itself is not known for generous dividends. What sets it apart is not the payout but the extraordinary cash cushion relative to its size — a feature most listed small-cap pharma names do not share. Direct like-for-like peers are hard to pin down because Albert David is unusually small, unusually cash-heavy, and part-investment-holding in character.

With FII holding just 0.58% and DII about 1.6% (mainly General Insurance Corporation), the register is dominated by promoters. Of the ₹2.85 crore total dividend, roughly ₹1.78 crore flows to the Kothari promoter group and about ₹1.07 crore to public and institutional minority shareholders. Because the payout is modest and the amount is small in absolute terms, this is not a case of a large cash extraction — but it is worth flagging that in a loss-making year the controlling family is the primary recipient of a balance-sheet-funded distribution.

Since April 2020, dividends in India are taxed in the hands of the shareholder at their applicable income-tax slab rate (the company no longer pays Dividend Distribution Tax). The company must deduct TDS at 10% under Section 194 if a resident shareholder's total dividend from the company in a financial year exceeds ₹5,000 (for those without a valid PAN, TDS is higher at 20%). The TDS is not an extra cost — it is adjusted against the shareholder's final tax liability.

Albert David's FY26 final dividend of ₹5.00 per share is a study in the difference between a dividend being affordable and a dividend being earned. It is unquestionably affordable: a ₹276 crore cash-and-investment war chest covers the ₹2.85 crore outflow roughly 97 times over, and debt is negligible. But it is not earned by this year's operations — the company posted a net loss, negative operating cash flow and deeply negative free cash flow, and topped up short-term borrowings during the year.

Look past the headline loss and the picture is more nuanced: much of the red ink is investment mark-to-market swinging against the company, while core pharma sales actually grew in the March quarter. The balance sheet is genuinely strong; the operating business is genuinely sub-scale right now; and a new CEO has just taken charge. Income-focused readers get a modest, well-covered-by-cash but low-quality yield of about 0.70%. Value-focused readers get a stock trading near book value with two-thirds of its market cap in cash. Neither picture is a recommendation — the positives, negatives and risks are laid out so you can weigh them yourself.